iBio, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
iBio's Board amended its 2023 Omnibus Incentive Plan (effective October 14, 2026) to expand the equity pool available for employee grants. The Plan's share reserve will auto-increase by 5% of outstanding common stock annually (2027–2033), plus 3% of pre-funded warrant shares for 2027–2029. Concurrently, the company increased authorized shares from prior levels to 500M common and 1M preferred (501M total) via Certificate of Amendment filed October 16, 2026.
Why this rating
Equity pool expansion is routine for small-cap biotech. At ~$57.5M market cap, a multi-year 5% annual dilution is material but not immediately transformational; cumulative dilution manageable if plan drives retention/performance. No counterparties, pricing, or near-term cash impact disclosed.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.